Genetic medicine is accelerating in Japan

Saori Hayashi, Makoto Kubo, Kazuhisa Kaneshiro, Masaya Kai, Mai Yamada, Takafumi Morisaki, Yuka Takao, Akiko Shimazaki, Sawako Shikada, Masafumi Nakamura

研究成果: ジャーナルへの寄稿学術誌査読

6 被引用数 (Scopus)


Background: In 2018, BRACAnalysis® was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for BRCA1/2 genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, and medical management including prophylactic surgery and surveillance were covered by public insurance for BRCA1/2 mutation carriers who developed breast or ovarian cancer. The amount of BRCA1/2 genetic testing has been increasing recently, but the number of subjects and the impact of testing for patients’ outcomes remain unclear. Patients and methods: This study explored the potential number of patients who will be eligible for new insurance coverage for BRCA1/2 genetic testing. We analyzed 868 patients from 938 surgeries between January 2014 and September 2020 from our database. Results: Overall, 372 patients (43%) were eligible for new insurance coverage for BRCA1/2 genetic testing. The most common category was family history of breast or ovarian cancer within third-degree relatives. We found that 202 patients (23%) had family history of breast or ovarian cancer. In addition, the progression-free survival was significantly lower in triple-negative breast cancer patients aged 60 years or younger compared with the other patients (P = 0.0005). Conclusion: The genetic medicine for primary breast cancer patients with BRCA1/2 germline mutation is accelerating rapidly in Japan. Therefore, establishing a system for the genetic medicine would be urgent.

ジャーナルBreast Cancer
出版ステータス出版済み - 7月 2022

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 放射線学、核医学およびイメージング
  • 薬理学(医学)


「Genetic medicine is accelerating in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。